As the initial reporters of this event in PNH, we felt the need to address this problem therapeutically by hypothesizing that blockade of the complement cascade upstream of C5 may represent a promising strategy for treating C3-mediated extravascular hemolysis emerging in PNH during eculizumab treatment (141). The gene discussed is C3; the disease is paroxysmal nocturnal hemoglobinuria.